Andrew Guggenhime Vaxcyte, Inc. (PCVX) insider trading activity

Andrew Guggenhime is PRESIDENT AND CFO of Vaxcyte, Inc.. Currently has a direct ownership of 109,491 shares of PCVX, which is worth approximately $9.47 Million. The most recent transaction as insider was on Dec 18, 2024, when has been sold 8,000 shares (Common Stock) at a price of $88.88 per share, resulting in proceeds of $711,040. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 109K

21.14% 3M change

37.77% 12M change

Total Value Held $9.47 Million

ANDREW GUGGENHIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 18 2024	SELL Open market or private sale	$711,040 $88.88 p/Share	8,000 Reduced 6.81%	109,491 Common Stock
Dec 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 6.37%	117,491 Common Stock
Nov 18 2024	SELL Open market or private sale	$691,040 $86.38 p/Share	8,000 Reduced 6.81%	109,491 Common Stock
Nov 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 6.37%	117,491 Common Stock
Oct 25 2024	BUY Exercise of conversion of derivative security	$399,930 $20.93 p/Share	19,108 Added 14.86%	109,491 Common Stock
Oct 18 2024	SELL Open market or private sale	$4,860,660 $115.73 p/Share	42,000 Reduced 31.73%	90,383 Common Stock
Oct 18 2024	BUY Exercise of conversion of derivative security	$224,699 $5.35 p/Share	42,000 Added 24.08%	132,383 Common Stock
Sep 18 2024	SELL Open market or private sale	$931,760 $116.47 p/Share	8,000 Reduced 8.13%	90,383 Common Stock
Sep 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.52%	98,383 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$698,020 $110.15 p/Share	6,337 Reduced 6.55%	90,383 Common Stock
Aug 19 2024	SELL Open market or private sale	$629,600 $78.7 p/Share	8,000 Reduced 7.64%	96,720 Common Stock
Aug 19 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.1%	104,720 Common Stock
Jul 18 2024	SELL Open market or private sale	$653,280 $81.66 p/Share	8,000 Reduced 7.64%	96,720 Common Stock
Jul 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.1%	104,720 Common Stock
Jun 18 2024	SELL Open market or private sale	$577,760 $72.22 p/Share	8,000 Reduced 7.64%	96,720 Common Stock
Jun 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.1%	104,720 Common Stock
May 20 2024	SELL Open market or private sale	$599,440 $74.93 p/Share	8,000 Reduced 7.72%	95,679 Common Stock
May 20 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.16%	103,679 Common Stock
Apr 18 2024	SELL Open market or private sale	$492,560 $61.57 p/Share	8,000 Reduced 7.72%	95,679 Common Stock
Apr 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.16%	103,679 Common Stock
Mar 18 2024	SELL Open market or private sale	$554,560 $69.32 p/Share	8,000 Reduced 7.72%	95,679 Common Stock
Mar 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.16%	103,679 Common Stock
Mar 02 2024	SELL Payment of exercise price or tax liability	$271,532 $71.55 p/Share	3,795 Reduced 3.82%	95,679 Common Stock
Feb 29 2024	BUY Grant, award, or other acquisition	-	20,000 Added 16.74%	99,474 Common Stock
Feb 20 2024	SELL Open market or private sale	$600,160 $75.02 p/Share	8,000 Reduced 9.15%	79,474 Common Stock

Also insider at

MTCR

Metacrine, Inc. Healthcare

Director

CRBU

Caribou Biosciences, Inc. Healthcare

Director